Merus N.V.

MRUS

NL0011606264

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 18/07/2024 am IST			5-day change	1st Jan Change
56.55 ^USD	-3.89%		+1.31%	+105.64%

14/07	Certain Restricted Share Units of Merus N.V. are subject to a Lock-Up Agreement Ending on 14-JUL-2024.	CI
14/07	Certain Options of Merus N.V. are subject to a Lock-Up Agreement Ending on 14-JUL-2024.	CI

Merus B.V. announced that it has received $80 million in funding from Incyte Corporation

January 24, 2017

On January 24, 2017, Merus B.V. closed the transaction. The company issued securities pursuant to exemption provided under Regulation D.

Latest news about Merus N.V.

Certain Restricted Share Units of Merus N.V. are subject to a Lock-Up Agreement Ending on 14-JUL-2024.	14/07	CI
Certain Options of Merus N.V. are subject to a Lock-Up Agreement Ending on 14-JUL-2024.	14/07	CI
Certain Common Shares of Merus N.V. are subject to a Lock-Up Agreement Ending on 14-JUL-2024.	14/07	CI
Merus Begins Phase 2 Trial of Colorectal Cancer Drug Candidate	08/07	MT
Merus Initiates Mid-stage Study of Colorectal Cancer Combination Therapy	08/07	MT
Merus N.V. Announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 2L CRC	08/07	CI
Merus N.V. Announces Chief Medical Officer Changes	02/07	CI
Sector Update: Health Care Stocks Retreat Late Afternoon	02/07	MT
Merus Names New Chief Medical Officer	01/07	MT
Stifel Nicolaus Adjusts Merus N.V Price Target to $99 From $90, Maintains Buy Rating	17/06	MT
Merus Insider Sold Shares Worth $475,456, According to a Recent SEC Filing	13/06	MT
BMO Capital Raises Price Target on Merus to $91 From $84, Maintains Outperform Rating	04/06	MT
Canaccord Genuity Adjusts Price Target on Merus to $67 From $54, Maintains Buy Rating	04/06	MT
Merus Says Target Tumors in Lung Cancer Patients Decrease in Size After MCLA-129 Treatment	04/06	MT
Truist Securities Raises Price Target on Merus to $88 From $69, Maintains Buy Rating	03/06	MT
Merus N.V. Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab At the 2024 ASCO® Annual Meeting	02/06	CI
Merus Prices $400.2 Million Public Share Offering	30/05	MT
BofA Securities Adjusts Merus Price Target to $80 From $61, Maintains Buy Rating	29/05	MT
HC Wainwright Adjusts Price Target on Merus to $85 From $65, Maintains Buy Rating	29/05	MT
Merus Launches $300 Million Stock Offering	29/05	MT
Guggenheim Adjusts Merus Price Target to $93 From $57, Maintains Buy Rating	28/05	MT
BMO Capital Adjusts Merus Price Target to $84 From $58, Maintains Outperform Rating	28/05	MT
Stifel Adjusts Price Target on Merus to $90 From $65, Maintains Buy Rating	28/05	MT
Sector Update: Health Care Stocks Decline Late Friday Afternoon	25/05	MT
Top Midday Gainers	24/05	MT

Merus NV is the Netherlands - based biotechnology company, concentrated on developing differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's products engage cancer antigens and harness the power of the immune system to kill tumor cells by utilizing technology platform. One of the drug zenocutuzumab (Zeno), a Biclonics antibody, concentrates on helping patients with lung, pancreatic and other types of solid tumors. The company operates in the Netherlands and United States.

Sector

Biotechnology & Medical Research

Calendar

05/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Merus N.V.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

56.55 USD

Average target price

86.27 USD

Spread / Average Target

+52.56%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
MERUS N.V.	+105.64%	3.75B
VERTEX PHARMACEUTICALS INCORPORATED	+20.03%	126B
REGENERON PHARMACEUTICALS, INC.	+23.61%	117B
ARGENX SE	+22.59%	27.52B
BIONTECH SE	-18.07%	20.87B
GENMAB A/S	-14.08%	17.01B
BEIGENE, LTD.	-14.81%	16.26B
NEUROCRINE BIOSCIENCES, INC.	+9.78%	14.56B
WUXI APPTEC CO., LTD.	-46.10%	15.09B
SAREPTA THERAPEUTICS, INC.	+52.34%	13.89B

Bio Therapeutic Drugs

Merus N.V.

Equities

MRUS

NL0011606264

Biotechnology & Medical Research

Merus B.V. announced that it has received $80 million in funding from Incyte Corporation

Latest news about Merus N.V.

Chart Merus N.V.

Company Profile

Income Statement Evolution

Ratings for Merus N.V.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs